Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Cox

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2019
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusionS S Bielack, M C Cox, M Nathrath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusionS S Bielack, M C Cox, M Nathrath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALTL Arcaini, S Burcheri, A Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Leukemia|December 16, 2006
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patientsS A Pileri, S Ascani, M C Cox, et al.
Leukemia|June 22, 2001
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patientsG Visani, P Bernasconi, M Boni, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2019
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusionS S Bielack, M C Cox, M Nathrath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusionS S Bielack, M C Cox, M Nathrath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALTL Arcaini, S Burcheri, A Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Leukemia|December 16, 2006
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patientsS A Pileri, S Ascani, M C Cox, et al.
Leukemia|June 22, 2001
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patientsG Visani, P Bernasconi, M Boni, et al.
Pageof 5